We have employed a robust randomized controlled trial using this intrinsic fiber in individuals with obesity at high risk of developing T2D followed by state-of the-art phenotyping of metabolic health with a two-step hyperinsulinemic-euglycemic clamp to assess tissue-specific insulin sensitivity and magnetic resonance spectrometry (MRS) to measure liver fat accumulation, as well as dual X-ray absorptiometry (DEXA) scan, subcutaneous adipose tissue biopsies, and targeted metabolomics, which were combined with advanced gut microbiomics using phylogenetic profiling and deep metagenomic analysis. This evidence concerns the gene INS and Obesity.